跳至主要内容
临床试验/NCT07385365
NCT07385365尚未招募3 期

A Phase Ⅲ Randomized Clinical Study and Real World Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 3,142 人开始时间: 2026年2月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
尚未招募
入组人数
3,142
试验地点
1
主要终点
tumor-free survival rate

研究概览

简要总结

The research hypothesis is that the tumor-free survival rate of intermediate-risk breast cancer patients exempted from RNI is not inferior to that of those receiving RNI. Patients with intermediate-risk breast cancer have a relatively low local-regional recurrence rate whether they undergo RNI or not.Patients were randomly assigned to the RNI group and the non-RNI group.After radiotherapy,the patients are followed the efficacy and toxicities of radiotherapy are evaluated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients aged 18 or above
  • Undergo breast-conserving surgery or total mastectomy and axillary lymph node dissection or sentinel lymph node biopsy
  • The surgical margin was negative
  • Tumor stage:Patients who receive direct surgery : pT1-2N1M0, with at least one lymph node having macrometastasis and a tumor risk score of 0-2.For those who underwent surgery after neoadjuvant chemotherapy: cT1-2N1-2M0→ypT0-2N0M0 (cN+ with pathological confirmation), neoadjuvant Chemotherapy for ≥6 cycles.

排除标准

  • distant metastasis
  • metastasis of ipsilateral internal mammary, supraclavicular or subclavian lymph nodes
  • Had received chest radiotherapy in the past
  • Bilateral breast cancer
  • Pregnancy or lactation period
  • Other malignant tumors in the past or at the same time, and the tumor-free survival time is less than 5 years (excluding non-malignant melanoma skin cancer, papillary thyroid carcinoma/follicular carcinoma, cervical carcinoma in situ)

研究组 & 干预措施

Regional nodal irradiation

Experimental

woman with intermediate-risk Breast Cancer involve postoperative conventional fraction/moderate hypofraction/ultrahypofraction radiotherapy to the whole breast/Chest Wall and nodal region

干预措施: Regional nodal Radiotherapy (Radiation)

Non-Regional nodal irradiation

Active Comparator

woman with intermediate-risk Breast Cancer receive conventional fraction/moderate hypofraction/ultrahypofraction radiotherapy to the whole breast/Chest Wall after breast-conserving surgery or receive no radiotherapy modified radical operation.

干预措施: Non-Regional nodal Radiotherapy (Radiation)

结局指标

主要结局

tumor-free survival rate

时间窗: 5 year

次要结局

  • localregional recurrence(5 year)
  • overall survival(5 year)
  • acute toxicity(6 months)
  • late complication(5 year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Shulian Wang,MD

M.D.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

研究点 (1)

Loading locations...

相似试验